Comparing the current results to its competitors, Cingulate Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 33.18 %, recorded in the same quarter.
Cingulate Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical industry, which is highly competitive and driven by advancing technologies and proprietary products. It competes with both pharmaceutical and generic drug companies offering short-acting and extended-release branded products, as well as generic versions addressing unmet medical needs. Key competitive factors include oral administration, therapeutic efficacy (immediate onset and full active day duration), safety and tolerability profiles, market access, and pricing. Some competitors possess substantially greater financial, technical, and human resources. The company anticipates a decline in branded competition following the loss of exclusivity for Vyvanse. The founders and management team have prior experience at Pfizer Inc., Novartis International AG, and Sanofi S.A., all leading biopharmaceutical companies.
Galmed Pharmaceuticals Ltd's business model focuses on the development and commercialization of innovative therapeutic solutions, particularly in the field of liver and metabolic diseases.
Ironwood Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of medicines for gastrointestinal disorders. Their business model involves discovering, developing, and marketing innovative treatments for conditions like irritable bowel syndrome and chronic constipation. They aim to achieve growth and profitability by leveraging their research capabilities and collaborating with strategic partners in the healthcare industry.
Relmada Therapeutics Inc's business model revolves around the development and commercialization of innovative therapies for the treatment of central nervous system (CNS) disorders.
Supernus Pharmaceuticals Inc operates under a unique business model focused on the development and commercialization of innovative treatments for central nervous system (CNS) diseases. The company combines in-house expertise with strategic partnerships to efficiently advance and bring their products to market. By prioritizing CNS disorders and utilizing a collaborative approach, Supernus Pharmaceuticals strives to address unmet medical needs and improve the lives of patients.
Sources:
Cingulate Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cingulate Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
